JP2022523320A5 - - Google Patents

Info

Publication number
JP2022523320A5
JP2022523320A5 JP2021544320A JP2021544320A JP2022523320A5 JP 2022523320 A5 JP2022523320 A5 JP 2022523320A5 JP 2021544320 A JP2021544320 A JP 2021544320A JP 2021544320 A JP2021544320 A JP 2021544320A JP 2022523320 A5 JP2022523320 A5 JP 2022523320A5
Authority
JP
Japan
Application number
JP2021544320A
Other languages
Japanese (ja)
Other versions
JP2022523320A (ja
JPWO2020160121A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015638 external-priority patent/WO2020160121A1/en
Publication of JP2022523320A publication Critical patent/JP2022523320A/ja
Publication of JP2022523320A5 publication Critical patent/JP2022523320A5/ja
Publication of JPWO2020160121A5 publication Critical patent/JPWO2020160121A5/ja
Pending legal-status Critical Current

Links

JP2021544320A 2019-01-29 2020-01-29 加齢黄斑変性の処置のためのオリゴヌクレオチドおよび方法 Pending JP2022523320A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962798048P 2019-01-29 2019-01-29
US62/798,048 2019-01-29
PCT/US2020/015638 WO2020160121A1 (en) 2019-01-29 2020-01-29 Oligonucleotides and methods for the treatment of age-related macular degeneration

Publications (3)

Publication Number Publication Date
JP2022523320A JP2022523320A (ja) 2022-04-22
JP2022523320A5 true JP2022523320A5 (https=) 2023-02-06
JPWO2020160121A5 JPWO2020160121A5 (https=) 2023-02-06

Family

ID=71840609

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544320A Pending JP2022523320A (ja) 2019-01-29 2020-01-29 加齢黄斑変性の処置のためのオリゴヌクレオチドおよび方法

Country Status (4)

Country Link
US (1) US20220195428A1 (https=)
EP (1) EP3918072A4 (https=)
JP (1) JP2022523320A (https=)
WO (1) WO2020160121A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022230987A1 (https=) * 2021-04-30 2022-11-03

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
EP1791567B1 (en) * 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
CA2577519A1 (en) * 2004-08-23 2006-03-30 Nucleonics, Inc. Multiple rna polymerase iii promoter expression constructs
US20110130440A1 (en) * 2008-03-26 2011-06-02 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
US8057295B2 (en) * 2008-11-10 2011-11-15 Wms Gaming Inc. Wagering game having award group selection feature
US20110281933A1 (en) * 2010-05-13 2011-11-17 Saint Louis University Methods and compositions for the management of cardiovascular disease with oligonucleotides
US20120053227A1 (en) * 2010-08-27 2012-03-01 New York University miR-33 INHIBITORS AND USES THEREOF
US9241950B2 (en) * 2011-04-28 2016-01-26 New York University MiR-33 inhibitors and uses thereof to decrease inflammation
US20120301439A1 (en) * 2011-05-24 2012-11-29 Washington University Inhibition of choroidal neovascularization
US20140363469A1 (en) * 2012-01-19 2014-12-11 Alnylam Pharmaceuticals, Inc. Viral attenuation and vaccine production
US11046955B2 (en) * 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
GB201607797D0 (en) * 2016-05-04 2016-06-15 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Glaucoma therapy
US10426817B2 (en) * 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics

Similar Documents

Publication Publication Date Title
CL2025003481A1 (es) Anticuerpos anti-cd20 y estructuras car-t
JP2022523320A5 (https=)
CN306250207S (https=)
CN305453160S9 (https=)
CN305537141S (https=)
CN305533496S (https=)
CN305533460S (https=)
CN305533433S (https=)
CN305532605S (https=)
CN305530295S (https=)
CN305528345S (https=)
CN306246224S (https=)
CN306249661S (https=)
CN305868811S (https=)
CN306465520S (https=)
CN306450144S (https=)
CN306425055S (https=)
CN306416164S (https=)
CN306392372S (https=)
CN306391001S (https=)
CN306387677S (https=)
CN306292845S (https=)
CN306292444S (https=)
CN306292135S (https=)
CN305871171S (https=)